EANS-News: AGENNIX AG Appoints New Vice President of Clinical Development

Dr. Steven Simonson Hired to Lead Talactoferrin Sepsis Development
Program

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Personnel

Subtitle: Dr. Steven Simonson Hired to Lead Talactoferrin Sepsis
Development Program

Planegg/Munich (Germany), Princeton, NJ, USA and Houston, TX, USA
(euro adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) today
announced the appointment of Steven Simonson, M.D., M.H.S. as Vice
President, Clinical Development, reporting to Dr. Rajesh Malik, the
Company's Chief Medical Officer. In this newly-created position, Dr.
Simonson will lead the Company's sepsis development program with oral
talactoferrin.

Rajesh Malik, M.D., Chief Medical Officer, said, "I am delighted to
have Dr. Simonson join the team at Agennix. He has extensive
clinical, academic and industry experience, including running a
sepsis clinical development program at a major international
pharmaceutical company. He joins us at a critical time as we prepare
to initiate our Phase II/III trial with talactoferrin in severe
sepsis."

Dr. Simonson has fifteen years of pharmaceutical industry experience.
Prior to joining Agennix, Dr. Simonson held several senior positions
at AstraZeneca, most recently as Senior Director, Clinical Research,
Infection Therapeutic Area. In this position, he served as the lead
physician for a Phase II program in sepsis. Prior to his industry
career, Dr. Simonson held several academic positions at Duke
University Medical Center. He received his M.D. from Medical College
of Wisconsin and a Masters degree in Health Sciences from Duke
University School of Medicine. He is Board certified in Pulmonary,
Critical Care and Internal Medicine.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company's most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as
well as in severe sepsis. Talactoferrin is currently in Phase III
clinical trials in non-small cell lung cancer, and Agennix plans to
develop this program further for the treatment of severe sepsis.
Other clinical development programs include RGB-286638, a
multi-targeted kinase inhibitor in Phase I testing, and a topical gel
form of talactoferrin for diabetic foot ulcers. Agennix's registered
seat is in Heidelberg, Germany. The Company has three sites of
operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix
Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. There can be no guarantee
that the Company will move talactoferrin forward in development for
severe sepsis in a timely manner, if at all, or that talactoferrin
will ultimately be approved for sale in any indication in any
country. Forward-looking statements speak only as of the date on
which they are made and Agennix undertakes no obligation to update
these forward-looking statements, even if new information becomes
available in the future.

Agennix(TM) is a trademark of the Agennix group.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Agennix AG
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Tel.: +49 89 8565-2693
ir@agennix.com

In the USA: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Tel.: 609-524-5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Tel.: +49 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Tel.: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade